Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study

Table 5

Risk factors for MTCT of HBV.

	Case/exposed, %	Univariate OR (95% CI)	Adjusted OR (95% CI)
Age
<35	27/595, 4.54%	1
≥35	3/56, 5.36%	1.19 (0.35-4.06)
HBeAg status
Negative	8/186, 4.30%	1
Positive	22/465, 4.73%	1.10 (0.46-2.92)
HBV DNA before delivery
<10^6 copies/mL	14/264, 5.30%	1
≥10^6 copies/mL	16/387, 4.13%	1.39 (1.17-1.64)	1.21 (1.02-1.44)
ALT at baseline (U/L)
0-40	10/218, 4.59%	1
41-80	9/178, 5.06%	1.11 (0.44-2.79)
>80	11/255, 4.31%	0.94 (0.39-2.25)
Telbivudine treatment
No	29/400, 7.25%	1
Yes	1/251, 0.40%	0.05 (0.01-0.38)	0.07 (0.01-0.55)
Gestation week
≥37 weeks	29/620, 4.68%	1
<37 weeks	1/31, 3.23%	0.68 (0.09-5.16)
Mode of delivery
Vaginal delivery	22/148, 14.86%	1
Caesarean section	8/503, 1.59%	0.09 (0.03-0.22)	0.72 (0.31-1.69)
Fetal distress
No	27/515, 5.24%	1
Yes	3/136, 2.21%	0.41 (0.12-1.36)
Postpartum hemorrhage
No	28/614, 4.56%	1
Yes	2/37, 5.41%	1.20 (0.27-5.22)
Meconium staining of the amniotic fluid
No	27/521, 5.18%	1
Yes	3/130, 2.31%	0.43 (0.13-1.45)
Premature rupture of membrane
No	28/585, 4.79%	1
Yes	2/66, 3.03%	0.62 (0.14-2.67)